Drug Adherence Enhancement Market: Devices and Applications, 2018-2030

Drug Adherence Enhancement Market: Devices and Applications, 2018-2030

INTRODUCTION
Poor adherence to prescribed medications is a growing concern in the healthcare industry and is believed to be associated with negative health outcomes, inflated medical expenses, loss in productivity and, in certain cases, proves fatal as well. It has been estimated that, of the ~4 billion annual prescriptions filled by the retailers in the US, approximately 50% are not taken by patients in accordance to physicians’ instructions. According to the US Centers for Disease Control and Prevention (CDC), failure to comply to prescribed treatment regimens has been identified as the cause of 125,000 premature deaths, up to 69% of all rehospitalizations, and results in approximately USD 100-300 billion worth of avoidable annual healthcare spending. Further, the US pharmaceutical industry alone is estimated to suffer a loss of approximately USD 188 billion per year, due to low adherence to prescribed medications.

Lack of compliance to therapy is particularly prevalent among elderly patients suffering from chronic clinical conditions, such as cardiovascular disorders, metabolic disorders (e.g., diabetes), neurological and central nervous system related disorders (e.g., multiple sclerosis and Parkinson’s disease) and respiratory disorders (e.g., asthma and chronic obstructive pulmonary disease). It is estimated that overall cost of treatment for non-adherent patients is at least twice as high as patients who adhere to recommended therapy regimens. Studies have demonstrated that every one percent improvement in medication adherence can help the US healthcare industry save up to USD 2 billion, resulting in an increase in pharmaceutical revenues by ~USD 4 billion. As a result, several strategies have been / are being developed by pharmaceutical developers and healthcare providers to improve medication adherence. Such initiatives have been strengthened owing to the availability of connected devices and other digital solutions, which allow patients / healthcare providers to closely monitor and improve drug adherence.

The ‘Drug Adherence Enhancement: Devices and Applications, 2018-2030’ report features an extensive study of the current landscape and future outlook of the growing market for smart medication adherence devices that are either already commercialized or under development. This burgeoning field presently offers a lot of opportunities to innovation-driven start-ups and investors. Amongst other elements, the report features:

A discussion on the current market landscape of smart drug delivery devices for medication adherence (which include smart inhalers, smart injectors, smart wearable injectors and smart pills), featuring information on the developers, along with details on key product specifications, namely audio / visual reminders, connectivity features (USB connection, Bluetooth and / or cellular network), availability of companion mobile application(s) and / or web portal(s), data storage / cloud platform options, and availability of battery backup / rechargeable batteries.

A discussion on the current market landscape of smart accessory devices for medication adherence (including smart medication dispensers, smart pill bottles / caps, smart pill boxes and smart blister packs), featuring information on the various developers, along with details on key product specifications. The section also presents a list of compliance packaging systems, along with information on their developers.

A summary of the various guidelines issued by regulatory authorities to govern the development and approval of combination products (drugs and smart devices) across different geographical regions.

Detailed profiles of some of the leading players in the industry (based on a proprietary shortlisting criteria), highlighting a brief overview of the company, financial information (if available), details related to its products / offerings, clinical trial results, recent developments and a comprehensive future outlook.

Detailed case studies on the most common chronic disease indications, featuring disease epidemiology, an overview of the economic burden imposed due to non-adherence to prescribed treatment regimens and a history of drug development efforts along with details on the evolution of delivery devices / strategies for improving therapy adherence.

A comprehensive competitiveness analysis of connected smart drug delivery systems and smart accessory systems on the basis of supplier power and key product specifications.

An analysis of funding and investments made in companies focused in this domain; the analysis covers information on seed financing, venture capital financing, debt financing, other equity financing and grants / awards received by these companies.

An analysis of the partnerships that have been forged between companies in the recent past, covering acquisitions, treatment optimization agreements, distribution agreements, manufacturing and supply agreements, product improvement agreements, product development agreements, product commercialization agreements, licensing agreements, service alliances and other relevant deals inked in the period 2010-2018. It also highlights the number of intercontinental and intracontinental deals signed in the aforementioned time period.

A list of standalone mobile applications that have been developed / are being developed to enable patients to adhere to prescribed medication regimens, along with the USFDA’s regulations related to such applications. It also includes details on the various articles / publications that have reported the results achieved by using mobile applications for improving medication adherence among patients.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. We have segmented the market by type of solution (smart drug delivery devices and smart accessory devices), type of product (smart inhalers, smart injectors, smart wearable injectors, smart pills, smart medication dispensers, smart pill bottles / caps and boxes, smart blister packs and others), therapeutic areas (metabolic disorders, cardiovascular disorders, neurological and central nervous system related disorders, respiratory disorders, and others), route of administration (oral, injectable, inhalable and others) and geography (North America, Europe, Asia-Pacific and rest of the world). To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:
Bernard Vrijens (Chief Executive Officer, AARDEX Group)
Spencer Waugh (Chief Executive Officer, AceAge)
Josh Stein (Chief Executive Officer, AdhereTech)
Duilio Macchi (Chief Executive Officer, Amiko Digital Health)
Gaurav Patel (Chief Technical Officer, Cognita Labs)
Moses Zonana (Chief Executive Officer, Compliance Meds Technologies) and Danahlyn Tamola (Associate Marketing Manager, Compliance Meds Technologies)
Tina Valbh (Strategy and Business Development (Advisor), etectRx)
Jonathan Sacks (Chief Executive Officer and Chairman, PharmAdva)
Timo Heikkilä (Co-Founder and Chief Operating Officer, Popit Technologies)
Moore Greenberg (Founder, Wealth Taxi)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. Currently, over 60 smart drug delivery devices are either commercially available or are under development for improving adherence to medication. More than 50% of these devices are smart inhalers or smart injectors. Examples of smart inhalers and smart injectors include (in alphabetical order, no selection criteria) 3M™ Intelligent Control Inhaler (3M), BETACONNECT™ (Medicom Innovation Partner), eMDI™ (H&T Presspart), Flexi-Q eMU-P and Flexi-Q eMU-C (Elcam Drug Delivery Device), GoCap (Common Sensing), Propeller (Propeller Health), SMARTTURBO™, SMARTTOUCH™ and SMARTTOUCH™ AV (Adherium), and SmartPilot and YpsoMate Smart (Ypsomed).

2. In addition, there are close to 75 smart accessory devices that are either commercially available or are under development. Of these, over 40% are smart medication dispensers. Noteworthy examples of such products include (in alphabetical order, no selection criteria) Evondos® E300 (Evondos), HERO (HERO Health), Maya™ and Jon™ (MedMinder Systems), MedaCube (PharmaAdva) and Philips Medido (Philips), Pillo (Pillo Health) and SIMPLEMED+ (Vaica).

3. Around 70% of the companies that are involved in the development of smart drug delivery systems and smart accessory systems are small-sized players / start-ups (having less than 50 employees). Examples of such companies include (in alphabetical order, no selection criteria) Aerobit Health, Airbrio, Arthur Health, Cognita Labs, CuePath Innovation, DayaMed, etectRx, MedMinder Systems, PharmRight, Popit, Portal Instruments and Wealth Taxi.

4. Over 50 compliance packaging systems are available to promote medication adherence among patients suffering from chronic clinical conditions; these include blister packs, pouches and dose cups. Companies engaged in the development of such products include (in alphabetical order, no selection criteria) Dispill-USA (Dispill® Multi-dose Packaging), Keystone Folding Box (Ecoslide-RX, Key-Pak® and Key-Pak Plus™), Omnicell (Opti-Pak™ and SureMed®), Parata Systems (Parata PASS Pack™) and TCGRx (AdherePac™ and AdhereCard™)

5. Many standalone mobile applications are also available for improving compliance to prescribed therapeutic regimens. As of July 2018, over 200 such mobile applications, having user ratings of more than four, were available on Google Play Store. It is worth mentioning that more than 70% smart drug delivery and accessory devices that we came across have a supporting mobile application.

6. Close to 180 partnerships have been inked between various stakeholders within the industry over the last few years; of these, over 100 collaborations were signed since 2016. Most of the deals that we came across were product development agreements (53%), signed between players to include new features in their products or advance their development programs. Examples of recently established deals include collaborations between Ypsomed and JDRF (August 2018), Adherium and Vitalus Health (August 2018), Amiko Digital Health and Luz Saúde (July 2018), Becton Dickinson and Helmer Scientific (June 2018), Common Sensing and Flex (May 2018), and Compliance Meds Technologies and Oracle Health Sciences (April 2018).

7. Since 2001, nearly USD 2.5 billion has been invested in companies operating in the field of medication adherence. Interestingly, close to half of the total amount (USD 1.1 billion) was raised between 2015 and August 2018, indicating the rising interest of strategic investors in this domain. Examples of players that have managed to secure capital investments in multiple rounds include Proteus Digital Health, NantHealth, Tandem Diabetes Care, Propeller Health and Cellnovo.

8. The drug adherence market is expected to grow at an annualized rate of more than 15.4% between 2018 and 2030. It is important to highlight that North America (primarily the US) and Europe currently capture the largest share of the overall market. This is followed by Asia-Pacific and rest of the world. As the industry matures, we expect the market in Asia-Pacific to grow owing to the sizable user base in the region.

1.1. RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market over the coming 12 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

1.1. CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of smart / connected devices that are being developed for improving medication adherence among patients.

Chapter 3 provides a general overview about medication adherence and the various methods / parameters used to measure and track patient compliance to prescribed therapeutic regimens. It also includes brief discussion on various types of non-adherence to therapy exhibited by patients and different factors that are considered to be responsible for such practices. In addition, the chapter features a detailed discussion on how non-adherence to therapy is impacting the health of patients and the overall healthcare industry. Further, it includes a brief discussion on various traditional and modern strategies for overcoming poor therapy adherence in patients. The chapter also provides information on the different initiatives that have been undertaken by various organizations to promote medication adherence.

Chapter 4 includes information on over 60 smart drug delivery devices that are either commercialized or under different stages of development for improving medication adherence. The chapter includes the information on the developer companies and the type of smart drug delivery product they offer; these include smart inhalers, smart injectors, smart wearable injectors, smart pills and other such devices. In addition, the chapter includes an analysis based on key product specifications, namely audio / visual reminders, connectivity features (USB connection, Bluetooth and / or cellular network), availability of companion mobile application, and companion web portal, data storage / cloud platform options and availability of battery backup / rechargeable battery.

Chapter 5 includes information on over 70 smart accessory devices that are either commercialized or under different stages of development for improving medication adherence. The chapter includes information on the developer companies and the type of smart accessory product they offer; these include smart medication dispensers, smart pill bottles / caps, smart pill boxes, smart blister packs and others. In addition, the chapter includes an analysis on key product specifications, namely audio / visual reminders, connectivity features (USB connection, Bluetooth, Wi-Fi and / or cellular network), availability of companion mobile application, and companion web portal, data storage / cloud platform options and availability of battery backup / rechargeable battery. Further, the chapter includes a brief overview on compliance packaging and a list of key players with expertise in this domain.

Chapter 6 provides information on various guidelines issued by regulatory authorities to govern the development and approval of combination products (drugs and smart devices) across different geographical regions such as North America, Europe, Latin America, Asia Pacific and the Middle East.

Chapter 7 features detailed profiles of some of the leading stakeholders in the smart drug delivery systems market. Each profile includes a brief overview of the company, financial information (if available), details related to its products / offerings, clinical trial results, recent developments and a comprehensive future outlook.

Chapter 8 features detailed profiles of some of the leading stakeholders in the smart accessory systems market. Each profile includes a brief overview of the company, financial information (if available), details related to its products / offerings, clinical trial results, recent developments and a comprehensive future outlook.

Chapter 9 features case studies on the most common disease indications across metabolic disorders, respiratory disorders and autoimmune disorders. Each case study features a detailed description of the disease, its epidemiology, an overview of the economic burden imposed due to non-adherence to prescribed treatments for the disease and history of drug development along with the evolution of delivery devices / strategies focused on improving therapy adherence.

Chapter 10 presents a product competitiveness analysis of all connected smart drug delivery systems and smart accessory systems on the basis of supplier power and key product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 11 provides information on the funding and investments that have been made in both smart drug delivery systems and smart accessory systems in the recent past. The chapter includes details on various types of capital investments, such as seed financing, venture funding, debt financing and grants, received by companies, highlighting the growing interest of the venture capital community and other strategic investors in this domain.

Chapter 12 features an analysis of the recent collaborations and partnerships that have been inked amongst players in this market, covering several partnership models, namely acquisitions, treatment optimization agreements, distribution agreements, manufacturing and supply agreements, product improvement agreements, product development agreements, product commercialization agreements, licensing agreements, service alliances and others, that have been adopted by industry stakeholders in this domain. It includes a world map representation of all the deals inked in this field in the period 2010-2018, highlighting both intercontinental and intracontinental partnership activity.

Chapter 13 provides a brief overview of the increasing prominence of mobile applications in the healthcare industry and the various regulations laid down by the USFDA for such applications. It includes a list of applications that are available at Google Play Store for helping patients adhere to prescribed medication regimens. The chapter also provides information on the various articles / publications, featuring results of studies aimed to demonstrate the benefits of using mobile applications for improving medication adherence among patients.

Chapter 14 presents a comprehensive market forecast, highlighting the future potential of the market till 2030 based on multiple parameters, such as prices of novel solutions, indication / region specific adoption trends, and competitive landscape. We have provided an informed estimate on the likely evolution of smart drug delivery devices and smart accessory devices. In addition, we have segmented the market by type of product (smart inhalers, smart injectors, smart wearable injectors, smart pills, smart medication dispensers, smart pill bottles / caps and boxes, smart blister packs and others), therapeutic areas (metabolic disorders, cardiovascular disorders, neurological and central nervous system related disorders, respiratory disorders and others), route of administration (oral, injectable, inhalable and others) and geography (North America, Europe, Asia-Pacific and rest of the world).

Chapter 15 summarizes the overall report. The chapter provides a list of the key takeaways and presents our independent opinion on the medication adherence market, specific to smart drug delivery systems and smart accessory systems, based on the research and analysis described in the previous chapters.

Chapter 16 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Bernard Vrijens (Chief Executive Officer, AARDEX Group), Spencer Waugh (Chief Executive Officer, AceAge), Josh Stein (Chief Executive Officer, AdhereTech), Duilio Macchi (Chief Executive Officer, Amiko Digital Health), Gaurav Patel (Chief Technical Officer, Cognita Labs), Moses Zonana (Chief Executive Officer, Compliance Meds Technologies) and Danahlyn Tamola (Associate Marketing Manager, Compliance Meds Technologies), Tina Valbh (Strategy and Business Development (Advisor), etectRx), Jonathan Sacks (Chief Executive Officer and Chairman, PharmAdva), Timo Heikkilä (Co-Founder and Chief Operating Officer, Popit Technologies) and Moore Greenberg (Founder, Wealth Taxi).

Chapter 17 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 18 is an appendix, which provides the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies and organizations have been mentioned in the report:
1. 3M
2. 5AM Ventures
3. 7wire Ventures
4. 91streets Media Technologies
5. AARDEX Group
6. AARP
7. Abbott
8. Abiogenix
9. AceAge
10. Acintyo
11. Acta Distribution
12. ActiveCare
13. Adams Street Partners
14. AdhereTech
15. Adherium
16. Administración Nacional de Medicamentos, Alimentosy Tecnología Médica
17. Advent Venture Partners
18. Aerobit Health
19. AeroSonix
20. Agência Nacional de Vigilância Sanitária (National Health Surveillance Agency)
21. Aguettant
22. Air Liquide Healthcare
23. AIRBRIO
24. Airnest
25. Allscripts
26. Altran
27. Amarutek
28. Amazon
29. AMC Health
30. American Academy of Allergy, Asthma and Immunology
31. American Heart Association
32. Amerigroup
33. Amgen
34. Amiko Digital Health
35. ANTARGYAN CLOUDWORKS
36. ApnaCare India
37. Apollo Diabetes Care Management
38. Apolotus Health Solution
39. Apoteket
40. App Singularity
41. AppAttic
42. Appgraid Apps
43. AppQuik
44. AppTrailz
45. Aptar Pharma
46. Area9 Innovation
47. Arthur Health
48. Artmedus
49. ARTORG Center
50. AS PHARM SOFT
51. Asheville Angels
52. Asho Soft Tech
53. Asset Management Ventures
54. Asthma and Respiratory Foundation New Zealand
55. AstraZeneca
56. AT&T
57. Aterica Digital Health
58. August Faller Group
59. Auriga Partners
60. Australasian Medical & Scientific
61. Austrian Chamber of Pharmacists
62. Automated Security Alert
63. Aventyn
64. Avery Dennison Medical Solutions
65. Avnet Integrated Solutions
66. Baviux
67. Bayer
68. Becton Dickinson
69. BERG
70. Bigfoot Biomedical
71. BioAdvance
72. BioAssist
73. BIOCORP
74. BioMark Health
75. BioScience Managers
76. BIVA
77. BlackPearls
78. Blackberry
79. Blueprint Health
80. Boehringer Ingelheim
81. Bosch
82. Brain Tech
83. Brainovations Education Excellence
84. Breed Reply
85. Butterfly Ventures
86. C-Square Info Solutions
87. C3HealthLink
88. caiocrol
89. California HealthCare Foundation
90. California Highlands Addiction Treatment
91. Cambridge Enterprise
92. Cambridge Consultants
93. Canada Innovation Acceleration Investment
94. Capital Angels
95. Capital Royalty Partners II
96. Cardinal Health
97. CareCentra
98. CareConsult
99. CareZone
100. Catalent Pharma Solutions
101. Celgene
102. Cellnovo
103. Cenduit
104. Centers for Disease Control and Prevention
105. Centers for Medicare & Medicaid Services
106. Central Drugs Standard Control Organization
107. Centric Health
108. Chalmers Ventures
109. CheckTheMeds Technology
110. Children's Hospital of Philadelphia
111. China Food and Drug Administration
112. CHORDAS
113. Chronicare
114. Cigna Health Insurance
115. Cincinnati Children's Hospital Medical Center
116. Circadian Design
117. Clifton R Farris
118. CML Advocates Network
119. Cognita Labs
120. Cognitive Healthcare
121. Cohero Health
122. Colbert Packaging
123. Comisión Federal para la Protección contra Riesgos Sanitarios
124. Common Sensing
125. Community Care Network of Virginia
126. Companion Medical
127. Compliance Meds Technologies
128. Confrérie Clinique
129. Connecticut Children's Medical Center
130. Core Mobile
131. Credit Agricole Private Equity
132. Crux Product Design
133. CSL Behring
134. C Square Info Solutions
135. CUCO Health
136. CuePath Innovation
137. Curatio
138. Curis
139. Cyft
140. DayaMed
141. Debiotech
142. Decision Machines
143. DeepBench
144. Delphi Ventures
145. Desert Oasis Healthcare
146. DeskShare
147. Dexcom
148. Diabeloop
149. Diasend
150. Digital Pharmacist
151. Diplomat Pharmacy
152. Disetronic Group
153. Dispill-USA
154. DistriMedic
155. DocRoSh Health
156. Domain Associates
157. Dosecast
158. DoseCue
159. DoseSmart
160. DOTh Solutions
161. Douglas Pharmaceuticals
162. Drug Package
163. Duke University
164. DYN Diagnostics
165. EcoloPharm
166. Edmond de Rothschild
167. E Ink
168. Elcam Drug Delivery Devices (E3D)
169. Eli Lilly
170. Elkstone Capital Partners
171. EMedStore Pharma IT
172. emocha Mobile Health
173. Emperra E-Health Technologies
174. Enable Injections
175. Enercon Technologies
176. EnvoyHealth
177. Essex Woodlands
178. etectRx
179. ETHIO APPS
180. Eularis
181. European Investment Bank
182. European Medicines Agency
183. Evalan
184. Everwell Health Solutions
185. Everwin Precision Technology
186. Evondos
187. Excell Partners
188. Experts in Communications and Connectivity Technology (ECCT)
189. Express Scripts
190. Fagor Healthcare
191. Fedefarma
192. Fidelity International
193. FindAir
194. The Finnish Funding Agency for Technology and Innovation
195. Fletcher Spaght Ventures
196. Flex
197. Forbion Capital Partners
198. Frost & Sullivan
199. GalileoMD
200. Gecko Health Innovations
201. GenieMD
202. Genome BC
203. GIS Strategic Ventures
204. GlaxoSmithKline
205. Global Emerging Markets Group
206. Gloria Pharmaceuticals
207. GlucoRx
208. GoSmart
209. GoodCare Pharma
210. GoodRx
211. GoodVent Beteiligungsmanagement
212. H&T Presspart
213. H&Y Apps
214. Hackensack Meridian Health
215. HAP Innovations
216. Haselmeier
217. HCL Technologies
218. Health Bot
219. Health Canada
220. Health Care Originals
221. Health Department of Oslo
222. Health Mission
223. Health Monitor
224. HealthBeacon
225. Healthbox
226. HealthCare Ventures
227. Healthcom
228. Healtheoz
229. Healthio
230. HealthPrize Technologies
231. Health's Angel
232. Heitkamp & Thumann Group
233. Helmer Scientific
234. Hepatitis Victoria
235. HERO Health
236. Hexoskin
237. Hikma Ventures
238. Home Diagnostics
239. HP Labs
240. HTC
241. Human API
242. Humana
243. IAP Labs
244. IDEAL LIFE
245. ImageWare Systems
246. ImagineCare
247. Immunex
248. Information Mediary
249. Innospence
250. Innovation Zed
251. INRange Systems
252. Inspirit Innovations
253. Insulin Pump Hellas
254. Intelligent Devices SEZC
255. Intelligent Product Solutions
256. Intent Solutions
257. International Diabetes Federation
258. International Federation of Pharmaceutical Manufacturers and Associations
259. Intigate Technologies
260. Investitionsbank des Landes Brandenburg
261. Irody
262. IRWAA
263. iSense
264. ITmedicus
265. Itochu
266. IVAX
267. Jabil
268. Janssen Pharmaceutica
269. JDRF
270. Jiangsu Delfu Medical Device
271. Jones Packaging
272. Joslin Diabetes Center
273. Journey Health Labs
274. JVS Technologies
275. Kaiser Permanente Ventures
276. KCRise Fund
277. Keystone Folding Box
278. Konkuk University
279. Korl Medical Center
280. Kreos Capital
281. K-svets
282. Kuwait Investment Authority
283. Life Integrating Technologies and Experiences (LITE)
284. Life Sciences Angel Network
285. LifeMatters
286. LloydsPharmacy
287. Lohmann Therapie Systeme
288. lool Ventures
289. Lowcountry Angels
290. LoyAlerts
291. LSDinfotech
292. Luz Saúde
293. M Ventures
294. M2M Datasmart
295. Maangata Apps
296. Maccabi Healthcare Services
297. Mail-Meds
298. Maj Invest Equity
299. Manchac Technologies
300. Mango Health
301. Manrex
302. Manyeta
303. MAP Health Management
304. Marketaro
305. MassChallenge
306. Maxerence
307. McKesson
308. MeadWestvaco
309. MedApps
310. MedControl Technologies
311. MedCrypt
312. Medexpert
313. Medical International Research
314. Medical Research Institute of New Zealand
315. Medical Specialties Australia
316. Medication Solutions
317. Medicine-On-Time
318. Medico Pak
319. Medicom Innovation Partner
320. MedicPen
321. Medimate
322. Medipense
323. Medisafe
324. MedMinder Systems
325. Medocity
326. MedPak Pharmacy
327. MedReady
328. MedSmart
329. Medtronic
330. Medtrum
331. MENA Apps
332. Merck
333. Metro Health
334. Mevia
335. MicroHealth
336. Ministry of Food and Drug Safety
337. Ministry of Health, Labour and Welfare
338. MivaTek Smart Connect
339. Molina Healthcare
340. Montuno Software
341. Mount Sinai Health System
342. Movi
343. MphRx
344. Multiframes
345. Mylan
346. MyMeds
347. MyTherapy
348. NantHealth
349. Nath IT Solutions
350. National Competent Authority
351. National Consumers League
352. National Institutes of Health
353. National Institute of Mental Health (NIMH)
354. Navia Life Care
355. NaviMed
356. NBGI Ventures
357. NECTEC
358. Nemera
359. NESTA
360. Nestlé Health Science
361. New Directions Technology Consulting
362. New World Health
363. New Zealand Medical & Scientific
364. NexusLink Services
365. nGageIT Digital Medicine
366. Noble International
367. NOPII
368. Novalab Ibérica
369. Novartis
370. Novo Nordisk
371. Now Healthcare Group
372. NPS MedicineWise
373. Octopus Ventures
374. Office of the National Coordinator for Health Information Technology Omnicell
375. Omron Healthcare
376. One Drop
377. Onward Care Technologies
378. Oracle Health Sciences
379. Orbita
380. ORI Healthcare Fund
381. Otsuka Pharmaceutical
382. Oxford Finance
383. Oyster Capital Partners
384. P5 Health Ventures
385. Palladio Group
386. Parata Systems
387. Partners HealthCare
388. PatientPartner
389. PBJ Capital
390. Pear Therapeutics
391. Pegasystems
392. Peppermint VenturePartners
393. PhableCare
394. Pharmacell Medication Systems
395. Pharmaceutical and Medical Devices Agency
396. PharmAdva
397. PharmaSens
398. PharmRight
399. Philips
400. Phillips-Medisize
401. Phoenix Healthcare
402. Picomol Healthcare
403. PillDrill
404. Pillo Health
405. PillPack
406. Pitango Venture Capital
407. Play-it Health
408. PMA Pharmacy
409. Poliweb Graphics
410. Popit
411. Portal Instruments
412. Practo
413. Prescription Notification Group
414. Prescription Solutions
415. ProCare Rx
416. Propeller Health
417. Proteus Digital Health
418. PRPL
419. Qualcomm Life
420. Quantum Pharmaceutical
421. Quido Healthcare Services
422. QuiO Technologies
423. Quizora Media
424. Raffles Medical Group
425. Ramtin Software Solutions
426. Raneem Technologies
427. Recovery Centers of America
428. RemindTrac
429. Renata
430. Research Institute of the McGill University Health Centre
431. Resolve Digital Health
432. Respia
433. Rex Medical
434. Risk Cooperative
435. Robert Bosch Venture Capital
436. Roche
437. RockTenn
438. Rubin Medical
439. RxAdvance
440. RxNetworks
441. RXVIP Concierge
442. Safeguard Scientifics
443. Safeway
444. Sagentia
445. Samsung
446. Samsung NEXT
447. Sanner Group
448. Sanofi
449. Sanofi-Sunrise
450. Saudi Food and Drug Authority
451. Schreiner MediPharm
452. SCRA Technology
453. Second Technology Capital Investors
454. SentiCare
455. Seoul National University
456. Serendipity Partners
457. SHL Group
458. Silicon Valley Bank
459. Simplified APP Solutions
460. Sino Portfolio
461. Sinwho
462. SmarterHealth TechServe
463. Smartgateways
464. Smiths Medical
465. Smooth Apps Studio
466. SMRxT
467. Social Capital
468. Soft Industry Alliance
469. Sonceboz
470. SOOIL Development
471. South Carolina Angel Network
472. Spartanburg Angels
473. Spring Ridge Ventures
474. Sprint
475. Spyzar Studios
476. SR One
477. St. Helena Health
478. St. Jude Medical
479. STAAR Alert
480. Sunrise Labs
481. SuperAndroidApp
482. Swanhill Capital
483. Syqe Medical
484. Takeda Pharmaceutical
485. Tandem Diabetes Care
486. TCGRx
487. Techizer Tech Solutions
488. Tekes
489. TerraNovita
490. Teva Pharmaceutical
491. The Carlyle Group
492. The Cyto Cord Group
493. The Kroger
494. Therapeutic Goods Administration
495. Three Leaf Ventures
496. Tidepool
497. Tillotts Pharma
498. TimerCap
499. Tinylogics
500. Tonghua Dongbao Pharmaceutical
501. TowerView Health
502. TPG Biotech
503. Triad HealthCare Network
504. Tricella
505. Trinnovate Ventures
506. TriVentures
507. TypeZero Technologies
508. UNICUS HealthReach
509. United Family Healthcare
510. United States Food and Drug Administration
511. UnitedHealthcare
512. University of Cambridge
513. University of Arkansas for Medical Sciences
514. University of Toronto
515. University of Pittsburgh Medical Center
516. Urtech Manufacturing
517. Vaica
518. Valtronic
519. Vectura Group
520. Verizon Investments
521. Virbac
522. Vishnu Global Services
523. Vitalus Health
524. Walgreens
525. Waterline Ventures
526. Wcre8tive App Developer
527. Wealth Taxi
528. Web Coast Apps
529. Welkin Health
530. West Pharmaceutical Services
531. WestRock
532. Whisper Arts
533. WMM
534. World Allergy Organization
535. World Health Organization
536. WorldMedic
537. Wyeth-Ayerst Pharmaceuticals
538. Xcenda
539. Xhale
540. Ximedica
541. XINK Laboratories
542. YOURmeds
543. YPSOMED
544. Zaffre Investments
545. Zibdy
546. Zipit Wireless